# Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients

> **NCT04620304** · PHASE1 · COMPLETED · sponsor: **United BioPharma** · enrollment: 15 (actual)

## Conditions studied

- HIV-1 Infection

## Interventions

- **BIOLOGICAL:** UB-421 SC(dB4C7C22-6 mAb)

## Key facts

- **NCT ID:** NCT04620304
- **Lead sponsor:** United BioPharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-05-25
- **Final completion:** 2022-05-25
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-04-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04620304

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04620304, "Study for Evaluation of the Safety, Pharmacokinetics, and Antiviral Activity of UB-421 Subcutaneous Formulation Administered in HIV-1 Infected Treatment Naive Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04620304. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*